ImaginAb Overview

  • Year Founded
  • 2007

Year Founded

  • Status
  • Private

  • Employees
  • 13

Employees

  • Latest Deal Type
  • Later Stage VC

  • Latest Deal Amount
  • $12.8M

  • Investors
  • 10

ImaginAb General Information

Description

Developer of engineered antibody fragments designed to be used for diagnostic imaging and radioimmunotherapy. The company's fragments are based on a clinical product pipeline that comprises prostate stem cell antigen for prostate, bladder, and pancreatic cancer; J591 prostate-specific membrane antigen for prostate cancer, and T-cell co-receptors for cancer, providing healthcare professionals with new insights into patients' treatment of immuno-oncology therapies.

Contact Information

Website
imaginab.com
Ownership Status
Privately Held (backing)
Financing Status
Venture Capital-Backed
Corporate Office
  • 4500 Park Granada
  • Suite 202
  • Calabasas, CA 91302
  • United States
+1 (310)
Primary Industry
Drug Discovery
Other Industries
Biotechnology
Corporate Office
  • 4500 Park Granada
  • Suite 202
  • Calabasas, CA 91302
  • United States
+1 (310)

Want detailed data on 11M+ companies?

What you see here scratches the surface

Request a free trial

Want to dig into this profile?

We’ll help you find what you need

Learn more

ImaginAb Valuation & Funding

Deal Type Date Amount Raised to Date Post-Val Status Stage
11. Later Stage VC 03-Jun-2021 $12.8M Completed Clinical Trials - Phase 2
10. Secondary Transaction - Private Completed Clinical Trials - General
9. Debt - PPP 14-Apr-2020 Completed Clinical Trials - General
8. Later Stage VC 08-Oct-2018 Completed Clinical Trials - General
7. Later Stage VC 14-Sep-2017 Completed Pre-Clinical Trials
6. Later Stage VC (Series A3) 12-Apr-2016 Completed Pre-Clinical Trials
5. Later Stage VC (Series B) 08-May-2014 Completed Pre-Clinical Trials
4. Later Stage VC (Series A) 26-Mar-2012 Completed Pre-Clinical Trials
3. Grant 01-Nov-2011 $2.3M Completed Startup
2. Seed Round Completed Startup
To view ImaginAb’s complete valuation and funding history, request access »

ImaginAb Cap Table

Stock # of Shares
Authorized
Par Value Dividend Rate ($) Original
Issue Price
Liquidation Liquidation
Pref. Multiple
Conversion Price % Owned
Series C-2
Series C
Series B 5,867,347 $0.150000 $0.06 $0.98 $0.98 1x $0.98 7.95%
Series A 20,021,060 $0.150000 $0.03 $0.49 $0.49 1x $0.49 27.13%
To view ImaginAb’s complete cap table history, request access »

VC Exit Predictor

See how our proprietary methodology utilizes historical data sets to synthesize the likelihood of an acquisition, IPO, or no exit event. Get a detailed look at the calculations behind our predictions.

Opportunity Score

Calculated using Exit Type probabilities, the company’s stage, and PitchBook’s historical returns data.

Exit Type

Evaluates the likelihood of a successful exit for investors, and the most likely exit type.

ImaginAb Comparisons

Description
Primary
Industry
HQ Location
Employees
Total Raised
Post Valuation
Last
Financing
Details
Developer of engineered antibody fragments designed to be used for diagnostic imaging and radioimmunotherapy. The compan
Drug Discovery
Calabasas, CA
13 As of 2026

Abingdon, United Kingdom
 

Palo Alto, CA
 
Add Comparison

PitchBook’s comparison feature gives you a side-by-side look at key metrics for similar companies. Personalize which data points you want to see and create visualizations instantly.

Request a free trial

ImaginAb Competitors (73)

One of ImaginAb’s 73 competitors is Adaptimmune Therapeutics, a Formerly VC-backed company based in Abingdon, United Kingdom.

Company Name Financing Status Location Employees Total Raised Last Financing Date/Type Last Financing Amount
Adaptimmune Therapeutics Formerly VC-backed Abingdon, United Kingdom
MaveriX Oncology Venture Capital-Backed Palo Alto, CA
Inovio Pharmaceuticals Corporation Plymouth Meeting, PA
Ayala Pharmaceuticals Corporation Wilmington, DE
Cristal Therapeutics Venture Capital-Backed Maastricht, Netherlands
You’re viewing 5 of 73 competitors. Get the full list »

ImaginAb Patents

ImaginAb Recent Patent Activity

Publication ID Patent Title Status First Filing Date Technology (CPC) Citations
WO-2025064446-A1 Antigen binding constructs Inactive 19-Sep-2023
WO-2025064435-A1 Antigen binding constructs directed to integrin αvβ6 Inactive 19-Sep-2023
WO-2025064435-A8 Antigen binding constructs directed to integrin αvβ6 Inactive 19-Sep-2023
US-20250236668-A1 Antibodies and methods of making and using same Pending 08-Jul-2022
WO-2024011186-A2 Antibodies and methods of making and using same Inactive 08-Jul-2022 C07K16/28
To view ImaginAb’s complete patent history, request access »

ImaginAb Signals

Growth Rate

Weekly
Growth
Weekly Growth

Size Multiple

Median
Size Multiple

Key Data Points

Similarweb Unique Visitors

Majestic Referring Domains

PitchBook’s non-financial metrics help you gauge a company’s traction and growth using web presence and social reach.

Request a free trial

ImaginAb Investors (10)

Investor Name Investor Type Holding Investor Since Participating Rounds
Norgine Ventures Lender/Debt Provider Minority
Merck & Co. Corporation Minority
Adage Capital Management Hedge Fund Minority
Parker Institute for Cancer Immunotherapy Corporation Minority
Raptor Holdco GP. Venture Capital Minority
You’re viewing 5 of 10 investors. Get the full list »

ImaginAb FAQs

  • When was ImaginAb founded?

    ImaginAb was founded in 2007.

  • Where is ImaginAb headquartered?

    ImaginAb is headquartered in Calabasas, CA.

  • What is the size of ImaginAb?

    ImaginAb has 13 total employees.

  • What industry is ImaginAb in?

    ImaginAb’s primary industry is Drug Discovery.

  • Is ImaginAb a private or public company?

    ImaginAb is a Private company.

  • What is the current valuation of ImaginAb?

    The current valuation of ImaginAb is .

  • What is ImaginAb’s current revenue?

    The current revenue for ImaginAb is .

  • How much funding has ImaginAb raised over time?

    ImaginAb has raised $65.1M.

  • Who are ImaginAb’s investors?

    Norgine Ventures, Merck & Co., Adage Capital Management, Parker Institute for Cancer Immunotherapy, and Raptor Holdco GP. are 5 of 10 investors who have invested in ImaginAb.

  • Who are ImaginAb’s competitors?

    Adaptimmune Therapeutics, MaveriX Oncology, Inovio Pharmaceuticals, Ayala Pharmaceuticals, and Cristal Therapeutics are some of the 73 competitors of ImaginAb.

Data Transparency

  • Meet our data hygiene team

    Discover how our experts ensure you’re getting the most accurate financial data in the industry.

    Read more
  • How PitchBook sources data

    Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.

    Discover our process